Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: Results of a randomized trial

Journal of Clinical Oncology

Volumn 21, Issue 15, 2003, Pages 2896-2903

  André, Thierry ^a   Colin, Philippe ^a   Louvet, Christophe ^a   Gomelin, Erik ^a   Bouche, Olivier ^a   Achille, Emmanuel ^a   Colbert, Nicolas ^a   Boaziz, Catherine ^a   Piedbois, Pascal ^a   Tubiana Mathieu, Nicole ^a   Boutan Laroze, Arnaud ^a   Flesch, Michel ^a   Buyse, Marc ^a   De Gramont, Aimery ^a  

^a Hopital St Joseph   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; HUMAN; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADULT; CHI SQUARE DISTRIBUTION; COLON TUMOR; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0042887580     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.10.065     Document Type: Article

References (31)

1. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
2. Budd GT, Fleming TR, Bukowski RM, et al: 5-Fluoruracil and folinic acid in the treatment of metastatic colorectal cancer: A randomized comparison-A Southwest Oncology Group Study. J Clin Oncol 5:272-277, 1987
3. Petrelli N, Herrera L, Rustum Y, et al: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5:1559-1565, 1987
4. Petrelli N, Douglass HO, Herrera L, et al: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial-Gastrointestinal Tumor Study Group. J Clin Oncol 7:1419-1426, 1989
5. Poon MA, O'Connell MJ, Moertel CG, et al: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7:1407-1418, 1989
6. Buroker TR, O'Connell MJ, Wieand HS, et al: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12:14-20, 1994
7. Machover D, Goldschmidt E, Chollet P, et al: Treatment of advanced colorectal and gastric adenocarcinomas with FU combined with high-dose folinic acid. J Clin Oncol 4:685-696, 1986
8. de Gramont A, Bosset J-F, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 15:808-815, 1997
9. Haller DG, Catalano PJ, MacDonald JS, et al: Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: Five year report of INT-0089. Proc Am Soc Clin Oncol 17:256a, 1998 (abstr 982)
10. O'Connell MJ, Laurie JA, Kahn M, et al: Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16:295-300, 1998
11. Buyse M, Piedbois P: Should Dukes' B patients receive adjuvant therapy? A statistical perspective. Semin Oncol 28:20-24, 2001 (suppl 1)
12. Mamounas E, Wieand S, Wolmark N, et al: Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17:1349-1355, 1999
13. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators: Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 17:1356-1363, 1999
14. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil as adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352-358, 1990
15. IMPACT study group: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345:939-944, 1995
16. André T, Colin P, Louvet C, et al: Randomized adjuvant study comparing two schemes of 5-fluorouracil and leucovorin in stage B2 and C colon adenocarcinoma: Study design and preliminary safety results. Semin Oncol 28:35-40, 2001 (supp 1)
17. Meta-Analysis Group in Cancer: Toxicity of 5-fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. J Clin Oncol 16:3537-3541, 1998
18. Lokich JJ, Ahlgren JD, Gullo JJ, et al: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study. J Clin Oncol 7:425-432, 1989
19. Hansen RM, Ryan L, Anderson T, et al: Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 88:668-674, 1996
20. Sobrero AF, Aschele C, Bertino JR: Fluorouracil in colorectal cancer: A tale of two drugs-Implications for biochemical modulation. J Clin Oncol 15:368-381, 1997
21. O'Connell MJ, Mailliard JA, Kahn MJ, et al: Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15:246-250, 1997
22. Wolmark N, Rockette H, Mamounas E, et al: Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17:3553-3559, 1999
23. Wolmark N, Bryant J, Smith R, et al: Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. J Natl Cancer Inst 90:1810-1816, 1998
24. Rothenberg ML, Meropol NJ, Poplin EA, et al: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 19:3801-3807, 2001
25. Saini A, Cunningham D, Norman AR, et al: Multicentre randomized trial of protracted venous infusion (PVI) 5 FU compared to 5 FU/folinic acid (FU/AF) as adjuvant therapy for colorectal cancer. Proc Am Soc Clin Oncol 19:240a, 2000 (abstr 928)
26. Poplin E, Benedetti J, Estes N, et al: Phase III randomized trial of bolus FU/ leucovorin/levamisole versus continuous infusion/levamisole as adjuvant therapy for high risk colon cancer (SWOG 941/INT-0153). Proc Am Soc Clin Oncol 19:240a, 2000 (abstr 931)
27. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
28. Douillard JY, Cunningham D, Roth A, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
29. Goldberg RM, Morton RF, Sargent DJ, et al: N9741: Oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (FU)/leucoverin (LV) or oxal + CPT11 in advanced colorectal cancer (CRC): Initial toxicity and response data from a GI intergroup study. Proc Am Soc Clin Oncol 21:128a, 2002 (abstr 511)
30. Tournigand C, Louvet C, Quinaux E, et al: FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC). Proc Am Clin Oncol 20:124a, 2001 (abstr 594)
31. de Gramont A, Boni C, Navarro M, et al: Oxaliplatin/FU/LV in adjuvant colon cancer: Safety results of the international randomized MOSAIC trial. Proc Am Soc Clin Oncol 21:132a, 2002 (abstr 525)